Mesothelioma Prognosis and Survival Rates: Women and Extended Pleurectomy Decortication

ByHolly Zink
Mesothelioma Prognosis and Survival Rates: Women and Extended Pleurectomy Decortication

Malignant pleural mesothelioma is a fast-spreading cancer tied to asbestos. Sadly, patients on standard treatments survive just 12–18 months. However, recent studies show better outcomes for some, especially women. They receive ePD surgery, part of a combined treatment.

Now, a new article examines mesothelioma patient outcomes. It looks at the factors impacting survival and the benefits of specific treatments.

Understanding Pleural Mesothelioma and the Pleural Space

Pleural mesothelioma is a cancer in the pleura, the thin membrane around the lungs and chest. It’s mainly caused by asbestos exposure, from work or the environment.

This cancer affects the pleural space, crucial for lung movement during breathing. A tumor or pleural effusion, excess fluid, can harm breathing and worsen mesothelioma symptoms.

Clinical Trial Insights: The MARS 2 Study

The MARS 2 trial, a major study in The Lancet Respiratory Medicine, looked at ePD for pleural mesothelioma. It found that chemotherapy alone led to better survival (24.8 months) than ePD (19.3 months). Also, the surgery group had worse quality of life, more side effects, and higher costs.

These results suggest we should rethink ePD for mesothelioma. This is due to the difficulty in fully removing the cancer and the long recovery time. The study highlights the need for expert surgeons and careful patient selection.

Prognostic Factors and Survival Rates in Women with Pleural Mesothelioma

A recent study focusing on female patients with pleural mesothelioma treated with ePD has provided valuable insights into prognostic factors and survival rates. The study enrolled 114 consecutive female patients treated over 11 years at a high-volume institution. Key findings include:

  1. Improved Survival Rates: Women with epithelioid histology who underwent ePD had a median survival of 44.4 months and a 5-year survival rate of 36.4%. This contrasts sharply with the general median survival of 12–18 months for unresectable patients.
  2. Impact of Complete Resection: Achieving macroscopic complete resection (MCR) significantly improved survival, with a hazard ratio (HR) of 0.3, indicating a 70% reduction in the risk of death compared to those without MCR.
  3. Other Prognostic Factors: Early T status, adjuvant therapy, intraoperative heated chemotherapy (IOHC), age, and epithelioid histology were all associated with better survival outcomes.

Women with Pleural Mesothelioma

A study of women with pleural mesothelioma highlights the need for a combined treatment approach. It shows that women, especially those with the common epithelioid type, benefit. Their survival increases, and the risk of death after surgery drops. Trials like MARS 2 are crucial. They refine treatments and offer guidance for mesothelioma care.

Joining a trial can give mesothelioma patients access to new treatments, better care, and a chance to help research. As oncology advances, trials will be key in fighting mesothelioma. They bring hope for better outcomes and a higher quality of life.

Source:

Lapidot, Moshe, Emanuele Mazzola, and Raphael Bueno. “Prolonged Survival and Novel Prognostic Factors in Women with Pleural Mesothelioma Treated with Extended Pleurectomy Decortication.” Translational Lung Cancer Research 13, no. 4 (April 29, 2024): 811–20. https://doi.org/10.21037/tlcr-23-797.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…